Indegene Limited — Investor Meet, 29-01-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Indegene delivered a strong Q3 FY26, with revenue hitting $106.1 Mn (INR 942.1 Cr), up 30.8% YoY and 17.1% QoQ. Adjusted EBITDA grew 15.7% YoY to INR 174.7 Cr. Reported PAT was INR 102.6 Cr, flat QoQ due to transient one-time expenses and higher non-cash amortization. Strategic acquisitions like BioPharm and Warn & Co. deepen capabilities. Management highlights AI/tech-led productivity, with revenue per employee crossing $70K annually. Client relationships are strengthening, with 3 clients above $25M and 52 above $1M. Future profitability is expected to strengthen as integration synergies are realized.